Found 286 articles for: "biologics"
Development of a Clinical Pathway for Atopic Dermatitis Patients: A Case-Based Approach
December 2016 | Volume 15 | Issue 12 | Original Article | 1485 | Copyright © December 2016
BACKGROUND: Atopic dermatitis (AD) is a common chronic skin condition, associated with significant patient morbidity. There are a myriad of excellent evidenced based guidelines to guide clinicians by ...
Read MoreExtracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures
April 2016 | Volume 15 | Issue 4 | Supplement Individual Articles | 63 | Copyright © April 2016
Normal aging and photoaging of the skin are chronic processes that progress gradually. The extracellular matrix (ECM), constituting over 70% of the skin, is the central hub for repair and regeneration...
Read MoreEfficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris: a Randomized Phase III Study (PSO-FAST)
December 2015 | Volume 14 | Issue 12 | Original Article | 1468 | Copyright © December 2015
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) designed to improve treatment outcomes.
OBJECTIVE: To compare the ef...
Read MoreRituximab for the Treatment of Recalcitrant Chronic Autoimmune Urticaria
December 2015 | Volume 14 | Issue 12 | Editorials | 1387 | Copyright © December 2015
The Power of Combination Topical Therapy for Psoriasis
October 2015 | Volume 14 | Issue 10 | Original Article | 1113 | Copyright © October 2015
Psoriasis is a chronic inflammatory skin disease where the use of topical corticosteroids is a mainstream treatment. However, the continuous use of high potency topical corticosteroids is limited by a...
Read MoreAnti-IL-23 Phase II Data for Psoriasis: A Review
October 2015 | Volume 14 | Issue 10 | Original Article | 1093 | Copyright © October 2015
BACKGROUND: Monoclonal antibodies that target both Interleukin (IL)-12 and IL-23 have shown great efficacy in the treatment of psoriasis. Recent evidence suggests that IL-23 serves a more critical rol...
Read MoreTime to Raise the Bar to Psoriasis Area Severity Index 90 and 100
October 2015 | Volume 14 | Issue 10 | Editorials | 1086 | Copyright © October 2015
Tumor Necrosis Factor-α Inhibitor Use in Psoriasis Patients With a First-degree Relative With Multiple Sclerosis
August 2015 | Volume 14 | Issue 8 | Original Article | 876 | Copyright © August 2015
Tumor necrosis factor (TNF)-α inhibitors are currently the gold standard for treating moderate to severe plaque psoriasis and other immune-mediated diseases. The presence of previously existing ...
Read MoreBiologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis
August 2015 | Volume 14 | Issue 8 | Original Article | 846 | Copyright © August 2015
BACKGROUND/OBJECTIVE: Despite the aging population, few studies have documented the treatment of geriatric psoriasis. The purpose of this study is to compare the efficacy, safety, and prescribing patt...
Read MoreSecukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials
August 2015 | Volume 14 | Issue 8 | Original Article | 821 | Copyright © August 2015
BACKGROUND: Interleukin (IL)-17A is a key cytokine in the pathogenesis of psoriatic disease of the skin and joints. In phase 3 trials, secukinumab, a fully human anti–IL-17A monoclonal antibody,...
Read MoreEssential Truths for the Care and Management of Moderate-to-Severe Psoriasis
August 2015 | Volume 14 | Issue 8 | Original Article | 805 | Copyright © August 2015
Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologics for psoriasis are directed at mor...
Read MoreEmerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib
August 2015 | Volume 14 | Issue 8 | Original Article | 786 | Copyright © August 2015
BACKGROUND: Increased knowledge of the molecular regulatory mechanisms that contribute to the pathogenesis of psoriasis and other inflammatory diseases has created new opportunities for the developmen...
Read MoreRandomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design
August 2015 | Volume 14 | Issue 8 | Original Article | 777 | Copyright © August 2015
Intra-subject, left-right, randomized, controlled study designs are often used for proof-of-concept studies in dermatology. This design was used to evaluate the safety and efficacy of a topical soluti...
Read MoreSafety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
July 2015 | Volume 14 | Issue 7 | Original Article | 706 | Copyright © July 2015
BACKGROUND: Safety surveillance is needed for biologic therapies for psoriasis.
OBJECTIVE: To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab and other psoriasis t...
Read MoreFive-Year Trend in the Number of Dermatologic Clinical Drug Trials Registered on ClinicalTrials.gov
May 2015 | Volume 14 | Issue 5 | Original Article | 497 | Copyright © May 2015
BACKGROUND: There is a reported global decrease in the number of clinical trials conducted in recent years. We aimed to determine if this declining trend can be extrapolated to dermatologic clinical t...
Read MoreLeprosy Masquerading as Rheumatoid Arthritis
May 2015 | Volume 14 | Issue 5 | Editorials | 448 | Copyright © May 2015
Next-generation Biologics in the Management of Plaque Psoriasis: A Literature Review of IL-17 Inhibition
March 2015 | Volume 14 | Issue 3 | Original Article | 244 | Copyright © March 2015
Advances in the understanding of the pathogenesis of psoriasis have led to the development of biologic agents that target T cells and cytokines that play a specific role in the underlying inflammation...
Read MoreThe Use of a Reliable, Ubiquitous, Inexpensive, and User-Friendly Tablet-Based System to Track Target Lesion Improvements in Subjects With Plaque Psoriasis Treated With Clobetasol Propionate 0.05% Spray
March 2015 | Volume 14 | Issue 3 | Original Article | 236 | Copyright © March 2015
Ubiquitous electronic devices, such as smartphones and tablets, have the potential to enable a fundamental shift in the paradigm of healthcare as these devices may allow patients and health care provi...
Read MoreAn Update on the Diagnosis and Management of Hereditary Angioedema With Abnormal C1 Inhibitor
February 2015 | Volume 14 | Issue 2 | Original Article | 151 | Copyright © February 2015
Hereditary angioedema (HAE) is a rare genetic disease caused by a deficiency in functional C1-esterase inhibitor characterized by recurrent episodes of angioedema in the absence of associated urticari...
Read MoreClearance of Psoriasis: The Impact of Private Versus Public Insurance
February 2015 | Volume 14 | Issue 2 | Original Article | 119 | Copyright © February 2015
BACKGROUND: Psoriasis treatments and therapeutic response as they relate to private versus public patient insurance in the United States have not yet been reviewed. Improved understanding could clarif...
Read More